Global Supply Chain in Clinical Trials: How Drugs Reach Patients at Sites
When a patient at a trial site opens a kit and takes an investigational drug, a long chain of logistics made that moment possible. The Clarity Clinical Solutions video "Global Supply Chain in Clinical Trials" calls this chain the invisible engine of clinical research. It is easy to ignore until something goes wrong, and when something goes wrong, the whole study can be delayed.
The video breaks the supply chain into three stages: sourcing and manufacturing, distribution, and accountability. Every stage is tracked, and every stage has rules.
Stage one: making and blinding the drug
Every trial drug starts with the active pharmaceutical ingredient, the chemical that actually does the medical work. It is manufactured under strict good manufacturing practice, or GMP, conditions, then tested for purity and potency. The FDA's overview of current good manufacturing practices explains why this matters: these requirements exist to make sure products are consistently produced and controlled to quality standards, not just at the end but at every step.
The ingredient then goes to a packaging facility where it is formulated into tablets, capsules, or injectables. This is where blinding happens. In a blinded trial, the randomization schedule decides which kits contain active drug and which contain placebo. Labels show only the kit number, not the drug name. The active drug and the placebo look, taste, and weigh the same, so neither the patient nor the site staff can tell them apart.
This labeling is not a courtesy; it is regulation. Under 21 CFR 312.6, an investigational drug's label must carry the statement "Caution: New Drug – Limited by Federal Law to Investigational Use," and it must not make any claims about safety or effectiveness. The blind can only work if the label leaks nothing about what is inside.
Stage two: shipping, cold chain, and depots
Distribution is where the geography gets complicated. Some drugs, particularly biologics and vaccines, need cold-chain shipping at 2 to 8 degrees Celsius. Others travel at ambient room temperature. Either way, the drug needs protective packaging and temperature monitoring for the whole journey.
Cold-chain logistics rely on qualified thermal shippers, phase-change materials, and data loggers that record temperature continuously. If a temperature excursion happens, the video describes the standard response: the drug is quarantined until stability data proves it is still safe to use. Nothing gets released on a guess.
Then there is the paperwork of crossing borders. Clinical trials that enroll patients in multiple countries need import permits and customs clearance in each one, and 21 CFR 312.110 sets out the import and export requirements for investigational drugs in the United States. Other countries have their own rules, and the video notes that every country regulates the import of unapproved investigational drugs differently. Regional depots hold temperature-controlled inventory and handle last-mile distribution to sites, which keeps stock close to where patients are.
The systems that manage all of this are called IRT, interactive response technology. IRT handles randomization, kit assignment, and resupply automation. When a site's inventory drops below a threshold, the system automatically generates a resupply order from the depot. Sites confirm receipt in the system, and the inventory picture updates in real time.
The video does not get into the newer layer on top of this, but it is worth knowing about: the Drug Supply Chain Security Act requires electronic tracking of prescription drugs through the U.S. supply chain, product by product. The same thinking, traceability at the unit level, is what clinical trial supply chains have done with kits for years.
Stage three: accountability from receipt to destruction
Drug accountability is the part of the supply chain that regulators care about most. It starts the moment a site receives kits. Every kit is logged by number, lot, and expiry date. Every time a kit is dispensed at a patient visit, that is recorded. At the end of the trial, a full reconciliation matches what was received against what was dispensed, returned, and destroyed.
Unused drugs are returned to the depot or destroyed, and the destruction certificates and reconciliation reports are archived as essential trial documents, usually for two years or more after the marketing application. This is not optional bookkeeping. The International Council for Harmonisation's good clinical practice guidelines (ICH E6) require investigators to maintain adequate records of the disposition of investigational products, including dates and amounts. If a regulator inspects the site and the numbers do not add up, that is a serious finding.
There is also a process for the rare moment when a blind has to be broken. If a patient has a medical emergency and the treatment assignment becomes clinically necessary, the IRT system can reveal a single patient's assignment. The reason is documented, and the patient's data is flagged in the statistical analysis to account for potential bias. It is a controlled exception, not a door left open.
The bottom line
The clinical trial supply chain is a logistics operation with lives on the line. Every step is tracked and validated. Temperature control is non-negotiable, because a single excursion can call a whole lot of drug into question. And accountability never stops, from manufacturing to destruction, every kit is accounted for. The next time a patient opens a kit at a site visit, remember the chain of custody that got it there.
This article is based on the Clarity Clinical Solutions video "Global Supply Chain in Clinical Trials." Watch it here: Global Supply Chain in Clinical Trials
References
- Clarity Clinical Solutions — "Global Supply Chain in Clinical Trials" (source video; three-stage structure, cold chain, IRT, and accountability sections). https://www.youtube.com/watch?v=jyhhpXZatnI
- FDA — Facts About the Current Good Manufacturing Practices (CGMPs) (supports the GMP manufacturing discussion). https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps
- eCFR — 21 CFR 312.6, Labeling of an Investigational New Drug (supports the blinded labeling discussion). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/section-312.6
- eCFR — 21 CFR 312.110, Import and Export Requirements (supports the cross-border shipping discussion). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/section-312.110
- FDA — Drug Supply Chain Security Act (DSCSA) (supports the unit-level traceability discussion). https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
- ICH — Efficacy Guidelines, E6 Good Clinical Practice (supports the drug accountability and records requirements). https://www.ich.org/page/efficacy-guidelines